RA Matters is an international project aiming to explore what matters most to people living with RA. Using online crowdsourcing to invite participants, RA Matters asks questions about relationships, activities, work and aspirations, in order to reveal the most important aspects of day-to-day life. RA Matters aims to elevate a global conversation that sheds light on what those with RA really want and – ultimately – help them live the best life possible.
The latest online tool to help make your treatment decisions.
We are looking for people to participate in a study to determine the usefulness of a web-based program designed to aid people with rheumatoid arthritis in making decisions to start or switch biologics.
If you have started discussing STARTING OR SWITCHING BIOLOGICS with your doctor, we invite you to participate in this study.
You may be eligible if you:
- Have a diagnosis of rheumatoid arthritis
- See a rheumatologist
- Have started discussing switching or starting biologic medication with your doctor
- Have a valid email and internet access
This study can be completed from home or anywhere with internet access. Any information you provide will be completely confidential. An honorarium will be provided for your time.
If you would like more information, please contact Jasmina Geldman, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email firstname.lastname@example.org. Please also visit our UBC Study Website for more information.
Effects of Social Networking on Chronic Disease Management in Arthritis
Do you have rheumatoid arthritis? Sign up for the Social Networking for Arthritis Patients (SNAP) study now.
The Social Networking for Arthritis Patients (SNAP) study is funded by The Rheumatology Research Foundation, a non-profit organization dedicated to research to improve the health of people with arthritis. Throughout the study, you will be having social interactions with patient representatives from The Arthritis Foundation, The International Foundation for Autoimmune Arthritis and The Arthritis Society. You may qualify for the study if you:
- Are 18 years or older
- Have been diagnosed by a doctor as having rheumatoid arthritis for 10 years or less
- Have an email address
- Able to communicate in English
- Are comfortable with using the internet
- Are familiar with social media
- Live in the United States of America or Canada
Your participation would be online only and you will receive compensation for your time and effort. Your expected time commitment is 6 months. The participant will be asked to access webpages and complete online questionnaires at three time points.Do you have rheumatoid arthritis? Sign up for the Social Networking for Arthritis Patients (SNAP) study now.
This study is being conducted by investigators at the University of Texas MD Anderson Cancer Center. To find out if you are eligible to participate, contact Jessica, research coordinator, at 1(713)563-8817 or email email@example.com.
Researchers at the University of Warwick have developed a new blood test to diagnosis early-stage arthritis years before the onset of physical and irreversible symptoms. The study, published in the journal Arthritis Research and Therapy, states that the test provides early diagnosis of osteoarthritis (OA). The test can distinguish between early OA and early-stage rheumatoid arthritis (RA) and other self-resolving inflammatory joint diseases.
The test identifies the chemical signatures found in the plasma of blood joint proteins damaged by oxidation, nitration and glycation (the modification of proteins with oxygen, nitrogen and sugar molecules). Continue reading
Do you have rheumatoid arthritis or care for someone who does? We want your valuable input
The Common Drug Review (CDR) is welcoming input on the manufacturer’s submission of sarilumab for the treatment of rheumatoid arthritis (RA) from patients and their caregivers.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.
These are the questions they are asking: Continue reading
Health Canada approves biosimilar etanercept for rheumatoid arthritis and ankylosing spondylitis
What does this mean for patients?
On August 31, 2016, the biosimilar etanercept (BRENZYS) was approved for the treatment of rheumatoid arthritis and ankylosing spondylitis.
BRENZYS is a subsequent entry biologic (biosimilar) to the Canadian authorized reference product, Enbrel. Both contain the active pharmaceutical ingredient, etanercept. Continue reading